Immune Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Immune Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) [Phase 3]
A Phase 3 trial evaluating Ianalumab versus placebo in addition to first-line corticosteroids for primary immune thrombocytopenia is active …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia [Phase 3]
Phase 3 trial evaluating the efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia is currently rec…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) [Phase 2, Phase 3]
Describes a pediatric Phase 2/3 study of intravenous efgartigimod in children aged 12 to under 18 with chronic immune thrombocytopenia that …
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia [Phase 1, Phase 2]
A Phase 1/2 study is evaluating pirtobrutinib for immune thrombocytopenia (ITP). The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia [Phase 2]
Pfizer is conducting a Phase 2 study to evaluate the safety and efficacy of PF-06835375 in primary immune thrombocytopenia, currently recrui…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura [Phase 1]
A Phase 1 trial evaluating dose-dense rituximab for high-risk newly diagnosed immune thrombocytopenia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders [Phase 2]
A Phase 2 clinical trial to assess the safety and tolerability of Tafasitamab in adults with primary autoimmune blood cell disorders, includ…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies [Phase 2]
Phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia who have had at least two prior therapies; the trial is…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab [Phase 2]
Phase 2 clinical trial evaluating Ianalumab in adults with primary immune thrombocytopenia and warm autoimmune hemolytic anemia who previous…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia [Phase 3]
Takeda-sponsored Phase 3 clinical trial evaluating mezagitamab in adults with chronic primary immune thrombocytopenia is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia [Phase 3]
Open-label Phase 3 trial evaluating intravenous immunoglobulin (5%) for Primary Immune Thrombocytopenia; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia [Phase 3]
A Phase 3 follow-up study of mezagitamab in adults with chronic primary immune thrombocytopenia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment [Phase 3]
This Phase 3 trial is evaluating the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia who failed first-line …
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) [Phase 2]
Phase 2 study to assess tolerability of ianalumab (VAY736) with investigator's choice thrombopoietin receptor agonist in patients with prima…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) [Phase 1]
Phase 1b long-term extension trial of RAY121 in multiple immunological diseases is currently enrolling by invitation, expanding early-phase …
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids [Phase 3]
Phase 3 study evaluating ianalumab versus placebo in addition to eltrombopag for adults with primary immune thrombocytopenia. The trial is c…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) [Phase 1, Phase 2]
A Phase 1b/2a clinical trial of Budoprutug for immune thrombocytopenia is currently recruiting, sponsored by Climb Bio, Inc.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Managed Access Programs for VAY736, Ianalumab
Clinical trial update indicating that managed access programs exist for the investigational antibody ianalumab (VAY736) from Novartis, for p…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: rhTPO Dose Escalation vs Eltrombopag Switch in ITP [NA]
Clinical trial comparing rhTPO dose escalation versus switching to eltrombopag in patients with primary immune thrombocytopenia. The study i…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) [Phase 3]
A Phase 3 clinical trial evaluating intravenous human normal immunoglobulin 10% in adults with chronic immune thrombocytopenia is currently …
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: TGD001 Treatment in Thrombotic Microangiopathies [Phase 1, Phase 2]
Clinical trial update for TGD001 in thrombotic microangiopathy and immune thrombocytopenia, currently not recruiting for Phase 1/Phase 2.
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients [Phase 3]
This update announces a Phase 3 safety and efficacy trial of QL0911 for pediatric immune thrombocytopenia that is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) [Phase 1]
This clinical trial update describes a Phase 1 study of PN20 in adults with primary immune thrombocytopenia (ITP). The sponsor is Chongqing …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases [EARLY_Phase 1]
This entry describes an early-phase UCAR-T trial targeting CD19/BCMA for autoimmune hematologic diseases and notes that recruitment is ongoi…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia [EARLY_Phase 1]
An early-phase clinical trial is evaluating the safety and preliminary efficacy of QT-019C, a universal allogeneic CAR-T therapy targeting C…